Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations

Therapeutic Drug Monitoring

Volumn 30, Issue 2, 2008, Pages 167-172

  Smith, Jeannina ^a   Andes, David ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

Antifungals; Fluconazole; Itraconazole; Posaconazole; Therapeutic drug monitoring; Voriconazole

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CLINICAL TRIAL; CONFERENCE PAPER; CRYPTOCOCCAL MENINGITIS; DRUG ELIMINATION; DRUG MONITORING; HUMAN; LIVER TOXICITY; MEDICAL LITERATURE; MONOTHERAPY; MYCOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHOTOPSIA; PRIORITY JOURNAL; THRUSH; VISUAL DISORDER;

ANTIFUNGAL AGENTS; DRUG MONITORING; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 42049108830     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318167d0e0     Document Type: Conference Paper

References (44)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692-1696.
2. Lin JS, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
3. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-1177.
4. Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;9:791-793.
5. Stamm AM, Diasio R, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83:236-242.
6. Hope WW, Warn PA, Sharp A, et al. Derivation of an in vitro drug exposure breakpoint for flucytosine against Candida albicans and the impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother. 2006;50:3680-3688.
7. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000;44:938-942.
8. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310-1313.
9. de la Vega L, Volkow SP, Yeates RA, et al. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Drugs Exp Clin Res. 1994;20:69-75.
10. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol. 1997;50:477-480.
11. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424-428.
12. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol. 1997;52:235-237.
13. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423-426.
14. Poirier JM, Berlioz F, Isnard F, et al. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie. 1996;51:163-167.
15. Berenguer J, Ali NM, Allende CM, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994;38:1303-1308.
16. Denning DW, Tucker RM, Hanson L, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791-800.
17. Tucker RM, Denning DW, Arathoon EG, et al. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol. 1990;23:593-601.
18. Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989;149:2301-2308.
19. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 1997;24:235-247.
20. Tricot G, Joosten E, Boogaerts MA, et al. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis. 1987;9(Suppl 1):S94-99.
21. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32:103-108.
22. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42:443-451.
23. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(Suppl 1):10-16.
24. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402
25. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.
26. Service RF. Going from genome to pill. Science. 2005;308:1858-1860.
27. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-1535.
28. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509-513.
29. Billaud EM, Pham MH, Berge M, et al. Voriconazole therapeutic drug monitoring (TDM) in cystic fibrosis lung transplanted patients. The 16th Congress of the International Society for Human and Animal Mycology (ISHAM), June 25-29, 2006, Paris, France. Abstract O-5-2006.
30. Mohammedi I, Piens MA, Padoin C, et al. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis. 2005;24:358-360.
31. Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39:1241-1244.
32. Lutsar I, Hodges MR, Tomaszeewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087.
33. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165-3169.
34. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005;49:3171-3177.
35. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48:137-142.
36. Diekema DJ, Messer SA, Hollos RJ, et al. Activities of caspofungin, itraconazole, posaconazole ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623-3626.
37. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819-826.
38. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
39. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-1572.
40. Pascual A, Cabandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
41. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57:218-222.
42. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50:1993-1999.
43. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658-666.
44. Pfaller M. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004;48:201-205.